  Up-regulation of the Hedgehog ( Hh) pathway is implicated in the genesis of a wide range of tumors including triple negative breast cancer ( TNBC). Sonidegib is a potent and selective oral inhibitor of Smo , a key component of the Hh signaling pathway. We designed a phase I clinical study to explore the combination of sonidegib plus docetaxel ( fixed dose at 75 mg/m EudraCT study number: 2013-001750-96. Study GEICAM/2012 -12. EudraCT study number: 2013-001750-96. Study GEICAM/2012 -12. ClinicalTrials.gov: NCT02027376.